Scientometric Analysis of Chemotherapy of Canine Leishmaniasis (2000-2020)

Overview

Journal Parasit Vectors

Publisher Biomed Central

Specialties Parasitology
Tropical Medicine

Date 2021 Jan 10

PMID 33422141

Citations 4

Authors

A I Olias-Molero

E Fontan-Matilla

M Cuquerella

J M Alunda

Affiliations

Soon will be listed here.

Abstract

Background: Zoonotic visceral leishmaniasis by Leishmania infantum is a first-order pathology in canine veterinary clinics in endemic areas. Moreover, canine infections are considered the main reservoir for human disease; despite their importance in the control of the disease within a One Health approach, no scientometric study has been published. Aims of the study included analyzing the impact of canine leishmaniasis (CanL) on the scientific literature, drugs or combinations used, trends in the period from 2000 to 2020 and efficacy criteria employed.

Methods: A Web of Science (WOS)-based analysis of publications on CanL and chemotherapy of the disease in the period 2000-2020 was carried out using a stepwise methodology. Data were analyzed by year, geographical origin, chemical groups, drugs and combinations, and efficacy criteria.

Results: Reports on CanL (n = 3324) represented < 16% of all publications on leishmaniasis (n = 20,968), and of these around 18% (n = 596) were related to chemotherapy. Publication records on CanL followed the distribution of the infection by L. infantum in endemic areas although Mediterranean countries were overrepresented in the reports on chemotherapy of CanL. Publications on the main antileishmanial drugs used in clinical practice showed a sustained tendency in the period analyzed. Pentavalent antimonials (Sb), alone or in combination with allopurinol, represented > 50% of all publications on chemotherapy of CanL despite the availability of more recently marketed drugs.

Conclusions: Chemotherapy of CanL still relies on Sb and combinations and to a lesser extent on miltefosine (MIL). Reports on chemotherapy are scarce and mostly publicly funded, and the variability of experimental conditions hampers the direct comparison of the efficacy of drugs, combinations and schedules. The vast majority of reports on efficacy do not include any information on supportive therapy; this reduces the actual value of the studies if intended for the practical management of the disease. Complete reports on the chemotherapy (etiological + symptomatic) would add value to the trials performed.

Citing Articles

Characterisation and evaluation of predisposing factors for the development of xanthinuria in dogs with leishmaniosis under allopurinol therapy.

Oliveira S, Arenas C, Dominguez-Ruiz M, Prosper E, Dias M, Leal R Parasit Vectors. 2025; 18(1):98.

PMID: 40065388 PMC: 11895311. DOI: 10.1186/s13071-025-06731-0.

In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis.

Roman-Alamo L, Allaw M, Avalos-Padilla Y, Manca M, Manconi M, Fulgheri F Pharmaceutics. 2023; 15(4).

PMID: 37111648 PMC: 10147000. DOI: 10.3390/pharmaceutics15041163.

Bibliometric Analysis of Veterinary Communication Education Research over the Last Two Decades: Rare Yet Essential.

Chen Z, Hsu Y, Lee J, Chou C Vet Sci. 2022; 9(6).

PMID: 35737308 PMC: 9227039. DOI: 10.3390/vetsci9060256.

Nutritional Modulation of the Immune Response Mediated by Nucleotides in Canine Leishmaniosis.

Segarra S Microorganisms. 2021; 9(12).

PMID: 34946204 PMC: 8703464. DOI: 10.3390/microorganisms9122601.

Antileishmanial Drug Discovery and Development: Time to Reset the Model?.

Olias-Molero A, de la Fuente C, Cuquerella M, Torrado J, Alunda J Microorganisms. 2021; 9(12).

PMID: 34946102 PMC: 8703564. DOI: 10.3390/microorganisms9122500.

References

Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling R . Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol. 2007; 5(11):873-82. DOI: 10.1038/nrmicro1748. View

Alvar J, Velez I, Bern C, Herrero M, Desjeux P, Cano J . Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7(5):e35671. PMC: 3365071. DOI: 10.1371/journal.pone.0035671. View

Petersen C, Barr S . Canine leishmaniasis in North America: emerging or newly recognized?. Vet Clin North Am Small Anim Pract. 2009; 39(6):1065-74, vi. PMC: 2824922. DOI: 10.1016/j.cvsm.2009.06.008. View

Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M . Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008; 8(3):191-9. DOI: 10.1016/S1473-3099(08)70043-4. View

Dantas-Torres F . The role of dogs as reservoirs of Leishmania parasites, with emphasis on Leishmania (Leishmania) infantum and Leishmania (Viannia) braziliensis. Vet Parasitol. 2007; 149(3-4):139-46. DOI: 10.1016/j.vetpar.2007.07.007. View

Alvar J, Canavate C, Molina R, Moreno J, Nieto J . Canine leishmaniasis. Adv Parasitol. 2004; 57:1-88. DOI: 10.1016/S0065-308X(04)57001-X. View

Morillas F, Sanchez Rabasco F, Ocana J, Martin-Sanchez J, Acedo C . Leishmaniosis in the focus of the Axarquía region, Malaga province, southern Spain: a survey of the human, dog, and vector. Parasitol Res. 1996; 82(6):569-70. DOI: 10.1007/s004360050164. View

Gradoni L . Canine Leishmania vaccines: still a long way to go. Vet Parasitol. 2015; 208(1-2):94-100. DOI: 10.1016/j.vetpar.2015.01.003. View

Velez R, Gallego M . Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy. Trop Med Int Health. 2020; 25(5):540-557. DOI: 10.1111/tmi.13382. View

10.

Costa D, Codeco C, Silva M, Werneck G . Culling dogs in scenarios of imperfect control: realistic impact on the prevalence of canine visceral leishmaniasis. PLoS Negl Trop Dis. 2013; 7(8):e2355. PMC: 3738479. DOI: 10.1371/journal.pntd.0002355. View

11.

Otranto D, Dantas-Torres F . The prevention of canine leishmaniasis and its impact on public health. Trends Parasitol. 2013; 29(7):339-45. DOI: 10.1016/j.pt.2013.05.003. View

12.

Seva A, Ovallos F, Amaku M, Carrillo E, Moreno J, Galati E . Correction: Canine-Based Strategies for Prevention and Control of Visceral Leishmaniasis in Brazil. PLoS One. 2016; 11(9):e0162854. PMC: 5015844. DOI: 10.1371/journal.pone.0162854. View

13.

Noli C, Auxilia S . Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet Dermatol. 2005; 16(4):213-32. DOI: 10.1111/j.1365-3164.2005.00460.x. View

14.

Backlund L, LEMPERG R, OTTOSSON L . Leg muscle strength in below-knee amputees. Acta Orthop Scand. 1968; 39(1):107-16. DOI: 10.3109/17453676808989445. View

15.

Oliva G, Roura X, Crotti A, Maroli M, Castagnaro M, Gradoni L . Guidelines for treatment of leishmaniasis in dogs. J Am Vet Med Assoc. 2010; 236(11):1192-8. DOI: 10.2460/javma.236.11.1192. View

16.

Travi B, Cordeiro-da-Silva A, Dantas-Torres F, Miro G . Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us. PLoS Negl Trop Dis. 2018; 12(1):e0006082. PMC: 5764232. DOI: 10.1371/journal.pntd.0006082. View

17.

Al-Mutawakel K, Scutaru C, Shami A, Sakr M, Groneberg D, Quarcoo D . Scientometric analysis of the world-wide research efforts concerning Leishmaniasis. Parasit Vectors. 2010; 3(1):14. PMC: 2845575. DOI: 10.1186/1756-3305-3-14. View

18.

Ramos J, Gonzalez-Alcaide G, Bolanos-Pizarro M . Bibliometric analysis of leishmaniasis research in Medline (1945-2010). Parasit Vectors. 2013; 6:55. PMC: 3602049. DOI: 10.1186/1756-3305-6-55. View

19.

Cortes S, Vaz Y, Neves R, Maia C, Cardoso L, Campino L . Risk factors for canine leishmaniasis in an endemic Mediterranean region. Vet Parasitol. 2012; 189(2-4):189-96. DOI: 10.1016/j.vetpar.2012.04.028. View

20.

Mattin M, Solano-Gallego L, Dhollander S, Afonso A, Brodbelt D . The frequency and distribution of canine leishmaniosis diagnosed by veterinary practitioners in Europe. Vet J. 2014; 200(3):410-9. DOI: 10.1016/j.tvjl.2014.03.033. View